Compare DERM & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | DOUG |
|---|---|---|
| Founded | 2014 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 162.3M |
| IPO Year | 2021 | 2021 |
| Metric | DERM | DOUG |
|---|---|---|
| Price | $7.11 | $1.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | 338.9K | ★ 382.5K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.72 | ★ 118.68 |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $955,578,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $1.53 |
| 52 Week High | $9.56 | $3.19 |
| Indicator | DERM | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 65.48 |
| Support Level | $7.00 | $1.55 |
| Resistance Level | $7.69 | $2.06 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 86.21 | 77.63 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.